194 related articles for article (PubMed ID: 8104200)
1. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
[TBL] [Abstract][Full Text] [Related]
2. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
[TBL] [Abstract][Full Text] [Related]
3. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
Steingard S; Allen M; Schooler NR
J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
[TBL] [Abstract][Full Text] [Related]
4. Clinical response to clozapine in patients with schizophrenia.
Pickar D; Litman RE; Hong WW; Su TP; Weissman EM; Hsiao JK; Potter WZ
Arch Gen Psychiatry; 1994 Feb; 51(2):159-60. PubMed ID: 8297214
[No Abstract] [Full Text] [Related]
5. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
6. Pimozide versus fluphenazine in ambulatory schizophrenics: A 12-month comparison study.
Donlon PT; Swaback DO; Osborne ML
Dis Nerv Syst; 1977 Feb; 38(2):119-23. PubMed ID: 319967
[TBL] [Abstract][Full Text] [Related]
7. High vs standard dosage fluphenazine HCL in acute schizophrenia.
Donlon PT; Meadow A; Tupin JP; Wahba M
J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
[TBL] [Abstract][Full Text] [Related]
8. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
9. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
[TBL] [Abstract][Full Text] [Related]
10. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
11. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
12. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
13. Fluphenazine plasma levels and clinical response.
Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
[TBL] [Abstract][Full Text] [Related]
14. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
16. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
Llorca PM; Wolf MA; Lançon C; Bougerol T
Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
[TBL] [Abstract][Full Text] [Related]
17. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.
Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH
Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874
[TBL] [Abstract][Full Text] [Related]
18. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of the alpha 2-adrenoreceptor antagonist idazoxan on hormonal responses and symptoms of hypoglycaemia in patients with type 1 diabetes mellitus.
Moberg E; Kollind M; Ostenson CG; Lins PE; Adamson U
Diabetes Metab; 1996 Feb; 22(1):31-6. PubMed ID: 8697293
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
